The endocannabinoid system and neurogenesis in health and disease

Neuroscientist

Volumn 13, Issue 2, 2007, Pages 109-114

  Galve Roperh, Ismael ^a   Aguado, Tania ^a   Palazuelos, Javier ^a   Guzmán, Manuel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Brain diseases; Cannabinoids; Neural progenitors; Neurogenesis

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABIS; ENDOCANNABINOID;

ALLERGIC ENCEPHALOMYELITIS; BRAIN DEVELOPMENT; CELL LINEAGE; CELL PROLIFERATION; DEMYELINATING DISEASE; EMBRYO DEVELOPMENT; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEUROMODULATION; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STROKE;

ANIMALS; BRAIN; BRAIN DISEASES; CELL DIFFERENTIATION; CELL PROLIFERATION; ENDOCANNABINOIDS; HUMANS; NERVE REGENERATION; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; RECEPTOR, CANNABINOID, CB1; STEM CELLS;

EID: 34047156445     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858406296407     Document Type: Review

References (30)

1. Aguado T., Monory K., Palazuelos J., Stella N., Cravatt B., Lutz B., and others. 2005. The endocannabinoid system drives neural progenitor proliferation. FASEB J 19: 1704 - 6.
2. Aguado T., Palazuelos J., Monory K., Stella N., Cravatt B., Lutz B., and others. 2006. The endocannabinoid system promotes gliogenesis by acting on neural progenitor cells. J Neurosci 26: 1551 - 61.
3. Arevalo-Martin A., Vela JM, Molina-Holgado E., Borrell J., Guaza C. 2003. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23: 2511 - 6.
4. Berghuis P., Dobszay MB, Wang X., Spano S., Ledda F., Sousa KM, and others. 2005. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci U S A 102: 19115 - 20.
5. Bilkei-Gorzo A., Racz I., Valverde O., Otto M., Michel K., Sarstre M., and others. 2005. Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proc Natl Acad Sci U S A 102: 15670 - 5.
6. Croxford JL, Miller SD 2003. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+) WIN55,212. J Clin Invest 111: 1231 - 40.
7. Curtis MA, Faull Rlm, Glass MK 2006. A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. J Chem Neuroanat 31: 210 - 5.
8. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt PM, Wolf S., and others. 2006. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49: 67 - 79.
9. Fernéndez-Ruiz J., Berrendero F., Hernéndez ML, Ramos JA 2001. The endogenous cannabinoid system and brain development. Trends Neurosci 23: 14 - 20.
10. Glass M., Van Dellen A., Blakemore C., Hannan AJ, Faull Rlm. 2004. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 123: 207 - 12.
11. Guzmén M. 2003. Cannabinoids: potential anticancer agents. Nat Rev Cancer 3: 745 - 55.
12. Jiang W., Zhang Y., Xiao L., Van Cleemput J, Ji S., Bai G., and others. 2005. Cannabinoid promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 115: 3104 - 16.
13. Jin K., Xie L., Kim SH, Parmentier-Batteur S., Sun Y., Mao XO, and others. 2004. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol 66: 204 - 8.
14. Jordan JD, He JC, Eungdamrong NJ, Gomes I., Ali W., Nguyen T., and others. 2005. Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII. J Biol Chem 280: 11413 - 21.
15. Kin SH, Won SJ, Mao XO, Ledent C., Jin K., Greenberg DA 2006. Role of neuronal nitric oxide synthase in cannabinoid-induced neurogenesis. J Pharmacol Exp Ther 319: 150-4.
16. Klein TW 2005. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5: 400 - 11.
17. Lie DC, Song HS, Colamarino A., Ming G., Gage FH 2004. Neurogenesis in the adult brain: new strategies for central nervous system diseases. Annu Rev Pharmacol Toxicol 44: 399 - 21.
18. Mackie K. 2006. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46: 101 - 22.
19. Marsicano G., Wotjak CT, Azad SC, Bisogno T., Rammes G., Cascio MG, and others. 2003. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84 - 8.
20. Mechoulam R., Spatz M., Shohami E. 2002. Endocannabinoids and neuroprotection. Science STKE 129: RE5.
21. Melis M., Pillolla G., Bisogno T., Minassi A., Petrosino S., Perra S., and others. 2006. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol Dis 24: 15-27.
22. Molina-Holgado E., Vela JM, Arevalo-Martin A., Almazan G., Molina-Holgado F., Borrell J., and others. 2002. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 22: 9742 - 53.
23. Nagayama T., Sinor AD, Simon RP, Chen J., Graham SH, Jin K., and others. 1999. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19: 2987 - 95.
24. Ortega-Gutierrez S., Molina-Holgado E., Arevalo-Martin A., Correa F., Viso A., Lopez-Rodriguez ML, and others. 2005. Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis. FASEB J 19: 1338 - 440.
25. Palazuelos J., Aguado T., Egia A., Mechoulam R., Guzmén M., Galve-Roperh I. 2006. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 20: 2405-7.
26. Piomelli D. 2003. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873 - 84.
27. Pryce G., Baker D. 2005. Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci 28: 272 - 6.
28. Ramirez BG, Blazquez C., Gomez del Pulgar T., Guzman M., de Ceballos ML 2005. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25: 1904 - 13.
29. Rueda D., Navarro B., Martínez-Serrano A., Guzmén M., Galve-Roperh I. 2002. The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap 1/B-Raf/ ERK pathway. J Biol Chem 277: 46645 - 50.
30. Williams E., Walsh FS, Doherty P. 2003. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J Cell Biol 160: 481 - 6.